Author Index Volume 51 (2016)
The issue number is given in front of the pagination
Abdin, E., M. Subramaniam, E. Achilla, S.A. Chong, J.A. Vaingankar, L. Picco, R. Sambasivam, S. Pang, B.Y. Chua, L.L. Ng, H.C. Chua, D. Heng, M. Prince and P. McCrone, The Societal Cost of Dementia in Singapore: Results from the WiSE Study (2) 439–449
Abe, M., see Sakai, K. (4) 997–1002
Aboulkassim, T., see Ongali, B. (4) 1183–1195
Abu-Hussien, M., see Frenkel-Pinter, M. (1) 165–178
Achilla, E., see Abdin, E. (2) 439–449
Acutis, P., see Costassa, E.V. (3) 875–887
Adam, P., S. Křížková, Z. Heger, P. Babula, V. Pekařík, M. Vaculovičová, C.M. Gomez, R. Kizek and V. Adam, Metallothioneins in Prion- and Amyloid-Related Diseases (3) 637–656
Adam, V., see Adam, P. (3) 637–656
Adlard, P.A., see Manso, Y. (1) 81–95
Adlard, P.A., see Xu, H. (2) 471–487
Agarwal, A.R., see Nunez, K. (1) 151–163
Aguayo, L.G., see Peters, C. (3) 689–699
Akhrif, A., see Pasquini, L. (1) 313–326
Alberici, A., see Pilotto, A. (2) 563–570
Alberici, A., see Premi, E. (1) 249–262
Alcalde-Cabero, E., see de Pedro-Cuesta, J. (4) 1003–1022
Al-Daghri, N.M., see Manousopoulou, A. (2) 333–338
Almazán-Isla, J., see de Pedro-Cuesta, J. (4) 1003–1022
Almeida, O.F.X., see Chang, L. (1) 197–212
Alyagor, I., see Frenkel-Pinter, M. (1) 165–178
Andrés-Benito, P., see Aso, E. (2) 489–500
Andriuta, D., V. Moullart, S. Schraen, A. Devendeville, M.-E. Meyer and O. Godefroy for the Alzheimer’s Disease Neuroimaging Initiative, What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects? (3) 793–800
Anfossi, M., see Montesanto, A. (4) 1265–1274
Annweiler, C., see Karakis, I. (2) 451–461
Antonell, A., see Sánchez-Valle, R. (3) 827–835
Apostolova, L.G., see Rattanabannakit, C. (4) 1145–1155
Archetti, S., see Premi, E. (1) 249–262
Asada, T., see Kida, J. (2) 405–415
Aso, E., P. Andrés-Benito, M. Carmona, R. Maldonado and I. Ferrer, Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer’s Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine (2) 489–500
Aspler, J., see Racine, E. (1) 1–9
Atkinson, R., see Femminella, G.D. (4) 1275–1289
Avellanal, F., see de Pedro-Cuesta, J. (4) 1003–1022
Babiloni, C., see Bocchetta, M. (1) 277–291
Babula, P., see Adam, P. (3) 637–656
Bagiella, E., see Luchsinger, J.A. (2) 501–514
Baioni, E., see Costassa, E.V. (3) 875–887
Bakchine, S., see Godefroy, O. (3) 815–825
Balasa, M., see Sánchez-Valle, R. (3) 827–835
Balin, B.J., see Itzhaki, R.F. (4) 979–984
Ball, M.J., see Itzhaki, R.F. (4) 979–984
Balzer-Geldsetzer, M., see Heßmann, P. (2) 545–561
Barak, Y., see Shelef, A. (1) 15–19
Bargalló, N., see Sánchez-Valle, R. (3) 827–835
Barocco, F., see Caffarra, P. (1) 27–31
Barthélemy, N.R., A. Gabelle, C. Hirtz, F. Fenaille, N. Sergeant, S. Schraen-Maschke, J. Vialaret, L. Buée, C. Junot, F. Becher and S. Lehmann, Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies (4) 1033–1043
Bartolomeo, P., see Migliaccio, R. (4) 1119–1130
Baruch, Y., see Shelef, A. (1) 15–19
Bascuñán, D., see Peters, C. (3) 689–699
Baugh, C.M., see Stern, R.A. (4) 1099–1109
Baum, E., see Heßmann, P. (2) 545–561
Beach, T.G., see Dugger, B.N. (2) 345–356
Beak, S.H., see Kim, Y.H. (1) 293–312
Bearer, E.L., see Itzhaki, R.F. (4) 979–984
Becher, F., see Barthélemy, N.R. (4) 1033–1043
Bechtel, C., see Remington, R. (4) 991–995
Behnisch, T., see Krishna, K. (3) 783–791
Beiser, A., see Karakis, I. (2) 451–461
Belfiore, M., see Manso, Y. (1) 81–95
Benito-León, J., I. Contador, A.J. Mitchell, Á. Domingo-Santos and F. Bermejo-Pareja, Performance on Specific Cognitive Domains and Cause of Death: A Prospective Population-Based Study in Non-Demented Older Adults (NEDICES) (2) 533–544
Bennett, S.A.L., see Granger, M.W. (3) 757–773
Benussi, L., see Bocchetta, M. (1) 277–291
Berg, D., see Pilotto, A. (2) 563–570
Berger, U., see Shelef, A. (1) 15–19
Bermejo-Pareja, F., see Benito-León, J. (2) 533–544
Bermúdez-Rattoni, F., see Morin, J.-P. (1) 69–79
Bernardi, L., see Bocchetta, M. (1) 277–291
Bertoux, M., see Wong, S. (3) 889–903
Bespalko, A., see Simonovitch, S. (3) 915–927
Bianchi, M., see Pilotto, A. (2) 563–570
Bigni, B., see Pilotto, A. (2) 563–570
Bihaqi, S.W., see Masoud, A.M. (4) 1257–1264
Binetti, G., see Bocchetta, M. (1) 277–291
Blanc, F., see Bousiges, O. (4) 1069–1083
Blanco-Gandía, M.C., see Bonet-Costa, V. (3) 701–711
Bocchetta, M., A. Mega, L. Bernardi, E. Di Maria, L. Benussi, G. Binetti, B. Borroni, R. Colao, G. Di Fede, S. Fosti-nelli, D. Galimberti, M. Gennarelli, R. Ghidoni, I. Piaceri, M. Pievani, C. Porteri, V. Redaelli, G. Rossi, S. Suardi, C. Babiloni, E. Scarpini, F. Tagliavini, A. Padovani, B. Nacmias, S. Sorbi, G.B. Frisoni, SINdem, A.C. Bruni, M. Bozzali, L. Parnetti, C. Ferrarese, S.F. Cappa, C. Marra, C. Masullo, I. Rainero, V. Silani, G. Sorrentino, G. Bruno, A. Cagnin, Genetic Counseling and Testing for Alzheimer’s Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol (1) 277–291
Bogucka-Kocka, A., see Pluta, R. (4) 1023–1031
Bogucki, J., see Pluta, R. (4) 1023–1031
Bombois, S., see Grangeon, L. (3) 905–913
Bonet-Costa, V., V. Herranz-Pérez, M.C. Blanco-Gandía, C. Mas-Bargues, M. Inglés, P. Gar-cia-Tarraga, M. Rodriguez-Arias, J. Miñarro, C. Borras, J.M. Garcia-Verdugo and J. Viña, Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer’s Disease (3) 701–711
Booth, S.L., see Karakis, I. (2) 451–461
Borras, C., see Bonet-Costa, V. (3) 701–711
Borroni, B., see Bocchetta, M. (1) 277–291
Borroni, B., see Pilotto, A. (2) 563–570
Borroni, B., see Premi, E. (1) 249–262
Bosch, B., see Sánchez-Valle, R. (3) 827–835
Bourre, B., see Grangeon, L. (3) 905–913
Bousiges, O., B. Cretin, T. Lavaux, N. Philippi, B. Jung, S. Hezard, C. Heitz, C. Demuynck, A. Gabel, C. Martin-Hunyadi and F. Blanc, Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer’s Disease and Dementia with Lewy Bodies (4) 1069–1083
Bozzali, M., see Bocchetta, M. (1) 277–291
Bozzali, M., see Serra, L. (2) 377–389
Braak, H., see Itzhaki, R.F. (4) 979–984
Bratasz, A., see Fang, D. (2) 571–580
Brooks, D.J., see Femminella, G.D. (4) 1275–1289
Brown, S.A., see Rattanabannakit, C. (4) 1145–1155
Bruni, A.C., see Bocchetta, M. (1) 277–291
Bruni, A.C., see Montesanto, A. (4) 1265–1274
Bruno G., see Bocchetta, M. (1) 277–291
Brzozowska, J., see Pluta, R. (4) 1023–1031
Buchert, R., see Suppa, P. (3) 867–873
Buée, L., see Barthélemy, N.R. (4) 1033–1043
Bullido, M.J., see Itzhaki, R.F. (4) 979–984
Bun, S., see Kida, J. (2) 405–415
Bush, A.I., see Manso, Y. (1) 81–95
Bush, A.I., see Xu, H. (2) 471–487
Busigny, T., see Lavallée, M.M. (4) 1225–1236
Byun, J., see Son, S.M. (4) 1197–1208
Cadenas, E., see Nunez, K. (1) 151–163
Caffarra, P., C. Ghetti, L. Ruffini, M. Spallazzi, A. Spotti, F. Barocco, C. Guzzo, M. Marchi and S. Gardini, Brain Metabolism Correlates of The Free and Cued Selective Reminding Test in Mild Cognitive Impairment (1) 27–31
Cagnin, A., see Bocchetta, M. (1) 277–291
Cai, Z.-Y., see Xu, Z.-Q. (1) 179–195
Calero, M., see de Pedro-Cuesta, J. (4) 1003–1022
Calero, O., see de Pedro-Cuesta, J. (4) 1003–1022
Caltagirone, C., see Serra, L. (2) 377–389
Calvó-Perxas, L., see Turró-Garriga, O. (2) 357–366
Cantu, R.C., see Stern, R.A. (4) 1099–1109
Cao, L., see Wang, H.-F. (1) 227–236
Cappa, S.F., see Bocchetta, M. (1) 277–291
Carare, R.O., see Manousopoulou, A. (2) 333–338
Carmona, M., see Aso, E. (2) 489–500
Carrasco, J., see Manso, Y. (1) 81–95
Carter, C., see Itzhaki, R.F. (4) 979–984
Casalone, C., see Costassa, E.V. (3) 875–887
Cascavilla, L., see D’Onofrio, G. (2) 427–437
Catania, M., see Costassa, E.V. (3) 875–887
Cauda, F., see Premi, E. (1) 249–262
Cercignani, M., see Serra, L. (2) 377–389
Cerón-Solano, G., see Morin, J.-P. (1) 69–79
Chai, Y.L., H. Kai-Hui Yeo, J. Wang, S. Hilal, M.K. Ikram, N. Venketasubramanian, B.-S. Wong and C. Li-Hsian Chen, Apolipoprotein ɛ4 is Associated with Dementia and Cognitive Impairment Predominantly Due to Alzheimer’s Disease and Not with Vascular Cognitive Impairment: A Singapore-Based Cohort (4) 1111–1118
Chaisson, C., see Stern, R.A. (4) 1099–1109
Chandler, J., see Racine, E. (1) 1–9
Chang, H., see Luchsinger, J.A. (2) 501–514
Chang, L., Y. Zhang, J. Liu, Y. Song, A. Lv, Y. Li, W. Zhou, Z. Yan, O.F.X. Almeida and Y. Wu, Differential Reg-ulation of N-Methyl-D-Aspartate Receptor Subunits is An Early Event in the Actions of Soluble Amy-loid-β1-40 Oligomers on Hippocampal Neurons (1) 197–212
Chang, Y.J., see Son, S.M. (4) 1197–1208
Charidimou, A., see Kim, Y.H. (1) 293–312
Chau, S.A., J. Chung, N. Herrmann, M. Eizenman and K.L. Lanctôt, Apathy and Attentional Biases in Alz-heimer’s Disease (3) 837–846
Chen, H., see Chu, S. (2) 525–532
Chen, H.-Y. and P.K. Panegyres, The Role of Ethnicity in Alzheimer’s Disease: Findings From The C-PATH Online Data Repository (2) 515–523
Chen, J.-M., see Yao, Q. (4) 1175–1182
Chen, K., see Xu, L. (4) 1045–1056
Chen, T., see Hong, X.-P. (2) 605–617
Chen, Y.-L., see Xu, Z.-Q. (1) 179–195
Chen, Z.-B., see Hong, X.-P. (2) 605–617
Cheng, Q., see Yao, Q. (4) 1175–1182
Cheng, X., see Chu, S. (2) 525–532
Chieppa, M.N., see Costassa, E.V. (3) 875–887
Cho, H., see Lyoo, C.H. (3) 671–675
Choi, J.Y., see Lyoo, C.H. (3) 671–675
Chong, S.A., see Abdin, E. (2) 439–449
Chu, S., F. Xu, Y. Su, H. Chen and X. Cheng, Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Com-parison of Inflammatory CAA and Amyloid-β-Related Angiitis (2) 525–532
Chua, B.Y., see Abdin, E. (2) 439–449
Chua, H.C., see Abdin, E. (2) 439–449
Chuen-Chung Chang, R., see Huang, C. (1) 213–226
Chukkapalli, S., see Singhrao, S.K. (4) 935–948
Chung, A., see Song, J.M., (2) 591–604
Chung, J., see Chau, S.A. (3) 837–846
Clare, L., C. Quinn, I.R. Jones and R.T. Woods, “I Don’t Think Of It As An Illness”: Illness Representations in Mild to Moderate Dementia (1) 139–150
Clerici, F., see Grande, G. (1) 57–67
Clerici, M., see Itzhaki, R.F. (4) 979–984
Colao, R., see Bocchetta, M. (1) 277–291
Colao, R., see Montesanto, A. (4) 1265–1274
Comes, G., see Manso, Y. (1) 81–95
Conde-Sala, J.L., see Turró-Garriga, O. (2) 357–366
Conejero-Goldberg, C., see Gomar, J.J. (4) 1085–1097
Contador, I., see Benito-León, J. (2) 533–544
Copenhaver, P.F., see Gray, N.E. (2) 391–403
Corona, C., see Costassa, E.V. (3) 875–887
Cosby, S.L., see Itzhaki, R.F. (4) 979–984
Cosseddu, M., see Pilotto, A. (2) 563–570
Costa, T., see Premi, E. (1) 249–262
Costassa, E.V., M. Fiorini, G. Zanusso, S. Peletto, P. Acutis, E. Baioni, C. Maurella, F. Tagliavini, M. Catania, M. Gallo, M. Lo Faro, M.N. Chieppa, D. Meloni, A. D’Angelo, O. Paciello, R. Ghidoni, E. Tonoli, C. Casalone and C. Corona, Characterization of Amyloid-β Deposits in Bovine Brains (3) 875–887
Cottini, E., see Pilotto, A. (2) 563–570
Cova, I., see Grande, G. (1) 57–67
Crean, S., see Singhrao, S.K. (4) 935–948
Cretin, B., see Bousiges, O. (4) 1069–1083
Crocco, P., see Montesanto, A. (4) 1265–1274
Cucumo, V., see Grande, G. (1) 57–67
Cullum, C.M., see LoBue, C. (3) 727–736
Czuczwar, S.J., see Pluta, R. (4) 1023–1031D’Angelo, A., see Costassa, E.V. (3) 875–887
D’Onofrio, G., F. Panza, D. Sancarlo, F.F. Paris, L. Cascavilla, A. Mangiacotti, M. Lauriola, G.H. Paroni, D. Seripa and A. Greco, Delusions in Patients with Alzheimer’s Disease: A Multidimensional Approach (2) 427–437
Dai, S.-X., see Li, W.-X. (2) 417–425
Dams, J., see Heßmann, P. (2) 545–561
Davies, P., see Gomar, J.J. (4) 1085–1097
Davis, S., see Guillot, F. (4) 1157–1173
De Deyn, P.P., see Niemantsverdriet, E. (1) 97–106
de la Monte, S.M., see Nunez, K. (1) 151–163
de la Monte, S.M., see Tong, M. (1) 123–138
de Nijs, L., see Sierksma, A.S.R. (3) 677–682
de Pedro-Cuesta, J., P. Martínez-Martín, A. Rábano, E. Alcalde-Cabero, F.J.G. López, J. Almazán-Isla, M. Ruiz-Tovar, M.-J. Medrano, F. Avellanal, O. Calero and M. Calero, Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders (4) 1003–1022
DeCarli, C., see Karakis, I. (2) 451–461
Delabrousse-Mayoux, J.-P., see Godefroy, O. (3) 815–825
Delgado-García, J.M., see Manso, Y. (1) 81–95
Demuynck, C., see Bousiges, O. (4) 1069–1083
Denney, D., see LoBue, C. (3) 727–736
Dent, K.A., see Xu, H. (2) 471–487
Deochand, C., see Tong, M. (1) 123–138
Devanand, D.P., see Luchsinger, J.A. (2) 501–514
Devendeville, A., see Andriuta, D. (3) 793–800
Di Fede, G., see Bocchetta, M. (1) 277–291
Di Maria, E., see Bocchetta, M. (1) 277–291
Diano, M., see Premi, E. (1) 249–262
Díaz-Cintra, S., see Morin, J.-P. (1) 69–79
Didsbury, J., see Tong, M. (1) 123–138
Dingova, D., T. Fazekas, P. Okuliarova, J. Strbova, M. Kucera and A. Hrabovska, Low Plasma Cholinesterase Activ-ities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer’s Disease (3) 801–813
Dodel, R., see Heßmann, P. (2) 545–561
Dodge, H.H., see Nishihira, J. (3) 857–866
Dols, A., see Gossink, F.T. (4) 1249–1256
Domingo-Santos, Á., see Benito-León, J. (2) 533–544
Douglas, J.T., see Fang, D. (2) 571–580
Dreier, A., see Eichler, T. (3) 847–855
Duan, Y.-J., see Hong, X.-P. (2) 605–617
Dubois, B., see Migliaccio, R. (4) 1119–1130
Dubois, B., see Suppa, P. (3) 867–873
Dugger, B.N., C.M. Whiteside, C.L. Maarouf, D.G. Walker, T.G. Beach, L.I. Sue, A. Garcia, T. Dunckley, B. Meechoovet, E.M. Reiman and A.E. Roher, The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer’s Disease (2) 345–356
Dumurgier, J., see Grangeon, L. (3) 905–913
Dunckley, T., see Dugger, B.N. (2) 345–356
Edison, P., see Femminella, G.D. (4) 1275–1289
Eichler, T., J.R. Thyrian, J. Hertel, S. Richter, D. Wucherer, B. Michalowsky, S. Teipel, I. Kilimann, A. Dreier and W. Hoffmann, Unmet Needs of Community-Dwelling Primary Care Patients with Dementia in Germany: Prev-alence and Correlates (3) 847–855
Eisenbaum, T., see Frenkel-Pinter, M. (1) 165–178
Eizenman, M., see Chau, S.A. (3) 837–846
Elahi, M., Z. Hasan, Y. Motoi, S.-E. Matsumoto, K. Ishiguro and N. Hattori, Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice (4) 1209–1224
Engelborghs, S. see Niemantsverdriet, E. (1) 97–106
Fan, Z., see Femminella, G.D. (4) 1275–1289
Fang, D., Z. Zhang, H. Li, Q. Yu, J.T. Douglas, A. Bratasz, P. Kuppusamy and S. ShiDu Yan, Increased Electron Paramagnetic Resonance Signal Correlates with Mitochondrial Dysfunction and Oxidative Stress in an Alz-heimer’s Disease Mouse Brain (2) 571–580
Farlow, M.R., see Rattanabannakit, C. (4) 1145–1155
Fazekas, T., see Dingova, D. (3) 801–813
Femminella, G.D., S. Ninan, R. Atkinson, Z. Fan, D.J. Brooks and P. Edison, Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer’s Disease and Parkinson’s Disease Dementia? (4) 1275–1289
Fenaille, F., see Barthélemy, N.R. (4) 1033–1043
Ferrarese, C., see Bocchetta, M. (1) 277–291
Ferrer, I., see Aso, E. (2) 489–500
Fiebach, J.B., see Suppa, P. (3) 867–873
Field, H., see Itzhaki, R.F. (4) 979–984
Finkelstein, D.I., see Xu, H. (2) 471–487
Fiocco, A.J., see Peck, K.J. (4) 949–959
Fiorini, M., see Costassa, E.V. (3) 875–887
Flanagan, E., see Ramanan, S. (2) 367–376
Flöel, A., see Külzow, N. (3) 713–725
Florian, H., A. Meier, S. Gauthier, S. Lipschitz, Y. Lin, Q. Tang, A.A. Othman, W.Z. Robieson and L.M. Gault, Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study (4) 1237–1247
Forlini, C., see Racine, E. (1) 1–9
Formenti, A., see Pilotto, A. (2) 563–570
Förstl, H., see Pasquini, L. (1) 313–326
Fortea, J., see Sánchez-Valle, R. (3) 827–835
Fostinelli, S., see Bocchetta, M. (1) 277–291
Fox, N.C., see Pasquier, F. (4) 1131–1143
Franko, B., see Granger, M.W. (3) 757–773
Frenkel, D., see Simonovitch, S. (3) 915–927
Frenkel-Pinter, M., S. Tal, R. Scherzer-Attali, M. Abu-Hussien, I. Alyagor, T. Eisenbaum, E. Gazit and D. Segal, Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neu-rotoxicity (1) 165–178
Frisoni, G.B., see Bocchetta, M. (1) 277–291
Fritts, N.G., see Stern, R.A. (4) 1099–1109
Fulop, T., see Itzhaki, R.F. (4) 979–984
Furmaga-Jabłońska, W., see Pluta, R. (4) 1023–1031
Gabel, A., see Bousiges, O. (4) 1069–1083
Gabelle, A., see Barthélemy, N.R. (4) 1033–1043
Galimberti, D., see Bocchetta, M. (1) 277–291
Galimberti, D., see Grande, G. (1) 57–67
Gallea, C., see Migliaccio, R. (4) 1119–1130
Gallo, M., see Costassa, E.V. (3) 875–887
Gandini, D., see Lavallée, M.M. (4) 1225–1236
Gao, S., see Rattanabannakit, C. (4) 1145–1155
Gao, W.-b., see Yang, C.-c. (1) 33–44
Gao, Y.-Y., see Xu, Z.-Q. (1) 179–195
Garbis, S.D., see Manousopoulou, A. (2) 333–338
Garcia, A., see Dugger, B.N. (2) 345–356
Garcia-Tarraga, P., see Bonet-Costa, V. (3) 701–711
Garcia-Verdugo, J.M., see Bonet-Costa, V. (3) 701–711
Gardini, S., see Caffarra, P. (1) 27–31
Garre-Olmo, J., see Turró-Garriga, O. (2) 357–366
Gascón-Bayarri, J. see Turró-Garriga, O. (2) 357–366
Gasparotti, R., see Premi, E. (1) 249–262
Gault, L.M., see Florian, H. (4) 1237–1247
Gauthier, S., see Florian, H. (4) 1237–1247
Gazit, E., see Frenkel-Pinter, M. (1) 165–178
Gazzina, S., see Premi, E. (1) 249–262
Gennarelli, M., see Bocchetta, M. (1) 277–291
Gerardin, E., see Grangeon, L. (3) 905–913
Gercel-Taylor, C., see Stern, R.A. (4) 1099–1109
Ghetti, C., see Caffarra, P. (1) 27–31
Ghidoni, R., see Bocchetta, M. (1) 277–291
Ghidoni, R., see Costassa, E.V. (3) 875–887
Ghiretti, R., see Grande, G. (1) 57–67
Gil-Kulik, P., see Pluta, R. (4) 1023–1031
Giralt, M., see Manso, Y. (1) 81–95
Girard, T.A., see Peck, K.J. (4) 949–959
Giulietti, G., see Serra, L. (2) 377–389
Godefroy, O., S. Bakchine, M. Verny, J.-P. Delabrousse-Mayoux, M. Roussel and J.-J. Pere on behalf of the REFLEX study group, Characteristics of Alzheimer’s Disease Patients with Severe Executive Disorders (3) 815–825
Godefroy, O., see Andriuta, D. (3) 793–800
Goeman, J., see Niemantsverdriet, E. (1) 97–106
Goldberg, T.E., see Gomar, J.J. (4) 1085–1097
Gomar, J.J., C. Conejero-Goldberg, P. Davies and T.E. Goldberg for the Alzheimer’s Disease Neuroimaging Initiative, Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer’s Disease (4) 1085–1097
Gomez, C.M., see Adam, P. (3) 637–656
Goossens, J., see Niemantsverdriet, E. (1) 97–106
Gossink, F.T., A. Dols, W.A. Krudop, S.A. Sikkes, C.J. Kerssens, N.D. Prins, P. Scheltens, M.L. Stek and Y.A.L. Pijnenburg, Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia (4) 1249–1256
Grande, G., V. Cucumo, I. Cova, R. Ghiretti, L. Maggiore, E. Lacorte, D. Galimberti, E. Scarpini, F. Clerici, S. Pomati, N. Vanacore and C. Mariani, Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation (1) 57–67
Grangeon, L., C. Paquet, S. Bombois, M. Quillard-Muraine, O. Martinaud, B. Bourre, R. Lefaucheur, G. Nicolas, J. Dumurgier, E. Gerardin, M. Jan, J.-L. Laplanche, K. Peoc’h, J. Hugon, F. Pasquier, D. Maltête, D. Hannequin, D. Wallon and the collaborators of the ePLM.fr group, Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein (3) 905–913
Granger, M.W., B. Franko, M.W. Taylor, C. Messier, P. St. George-Hyslop and S.A.L. Bennett, A TgCRND8 Mouse Model of Alzheimer’s Disease Exhibits Sexual Dimorphisms in Behavioral Indices of Cognitive Reserve (3) 757–773
Grassi, C., see Itzhaki, R.F. (4) 979–984
Gray, N.E., J.A. Zweig, C. Kawamoto, J.F. Quinn and P.F. Copenhaver, STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-β Toxicity (2) 391–403
Greco, A., see D’Onofrio, G. (2) 427–437
Griffin, W.S.T., see Itzhaki, R.F. (4) 979–984
Grimmer, T., see Pasquini, L. (1) 313–326
Grittner, U., see Külzow, N. (3) 713–725
Gualeni, V., see Premi, E. (1) 249–262
Guillot, F., S. Kemppainen, G. Lavasseur, P.O. Miettinen, S. Laroche, H. Tanila and S. Davis, Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer’s Disease (4) 1157–1173
Guo, X., see Xu, L. (4) 1045–1056
Gurevicius, K., see Leinonen, H. (1) 21–26
Guzzo, C., see Caffarra, P. (1) 27–31
Haas, J., see Itzhaki, R.F. (4) 979–984
Hägerström, D., see Smith, R. (2) 339–343
Hahn, A., see Külzow, N. (3) 713–725
Hamel, E. see Ongali, B. (4) 1183–1195
Hampel, H., see Suppa, P. (3) 867–873
Han, S.-H., see Moon, Y. (3) 737–745
Han, Y.-M., see Hong, X.-P. (2) 605–617
Hannequin, D., see Grangeon, L. (3) 905–913
Hansson, O., see Smith, R. (2) 339–343
Harding, A., see Singhrao, S.K. (4) 935–948
Hart Jr, J.., see LoBue, C. (3) 727–736
Hasan, Z., see Elahi, M. (4) 1209–1224
Hasegawa, M., see Sakai, K. (4) 997–1002
Hata, R., see Sakai, K. (4) 997–1002
Hattori, N., see Elahi, M. (4) 1209–1224
Haworth, J., M. Phillips, M. Newson, P.J. Rogers, A. Torrens-Burton and A. Tales, Measuring Information Processing Speed in Mild Cognitive Impairment: Clinical Versus Research Dichotomy (1) 263–275
Heger, Z., see Adam, P. (3) 637–656
Heitz, C., see Bousiges, O. (4) 1069–1083
Heng, D., see Abdin, E. (2) 439–449
Herranz-Pérez, V., see Bonet-Costa, V. (3) 701–711
Herrmann, N., see Chau, S.A. (3) 837–846
Hertel, J., see Eichler, T. (3) 847–855
Heßmann, P., G. Seeberg, J.P. Reese, J. Dams, E. Baum, M.J. Müller, R. Dodel and M. Balzer-Geldsetzer, Health-Related Quality of Life in Patients with Alzheimer’s Disease in Different German Health Care Settings (2) 545–561
Hezard, S., see Bousiges, O. (4) 1069–1083
Hidalgo, J. see Manso, Y. (1) 81–95
Higashiuesato, Y., see Nishihira, J. (3) 857–866
Hiki, Y., see Sakai, K. (4) 997–1002
Hilal, S., see Chai, Y.L. (4) 1111–1118
Himali, J.J., see Karakis, I. (2) 451–461
Hirtz, C., see Barthélemy, N.R. (4) 1033–1043
Ho, Y.-S., see Huang, C. (1) 213–226
Hodges, J.R., see Kumfor, F. (1) 237–248
Hodges, J.R., see Ramanan, S. (2) 367–376
Hodges, J.R., see Schubert, S. (3) 775–782
Hodges, J.R., see Wong, S. (3) 889–903
Hoe, H.-S., see Song, J.M., (2) 591–604
Hoffmann, W., see Eichler, T. (3) 847–855
Holstein, A., see Pasquier, F. (4) 1131–1143
Holtzman, D.M., see Simonovitch, S. (3) 915–927
Hong, S.K., see Lyoo, C.H. (3) 671–675
Hong, X.-P., T. Chen, N.-N. Yin, Y.-M. Han, F. Yuan, Y.-J. Duan, F. Shen, Y.-H. Zhang and Z.-B. Chen, Puerarin Ameliorates D-Galactose Induced Enhanced Hippocampal Neurogenesis and Tau Hyperphosphorylation in Rat Brain (2) 605–617
Hoogland, G., see Sierksma, A.S.R. (3) 677–682
Hornberger, M., see Ramanan, S. (2) 367–376
Hornberger, M., see Wong, S. (3) 889–903
Hrabovska, A., see Dingova, D. (3) 801–813
Huang, C., O. Tsz-Wa Ng, Y.-S. Ho, M.G. Irwin, R. Chuen-Chung Chang and G. Tin-Chun Wong, Effect of Contin-uous Propofol Infusion in Rat on Tau Phosphorylation with or without Temperature Control (1) 213–226
Huang, H., see Xu, Z.-Q. (1) 179–195
Huang, J.-F., see Li, W.-X. (2) 417–425
Huang, Y., see Lou, G. (4) 985–990
Hudson, A.P., see Itzhaki, R.F. (4) 979–984
Hugon, J., see Grangeon, L. (3) 905–913
Hwang, M.S., see Lyoo, C.H. (3) 671–675
Hynan, L.S., see LoBue, C. (3) 727–736
Ichise, M., see Luchsinger, J.A. (2) 501–514
Ihara, M., see Manousopoulou, A. (2) 333–338
Ikejima, C., see Kida, J. (2) 405–415
Ikezu, T., see Stern, R.A. (4) 1099–1109
Ikram, M.K., see Chai, Y.L. (4) 1111–1118
Imboden, H., see Ongali, B. (4) 1183–1195
Inglés, M., see Bonet-Costa, V. (3) 701–711
Iram, T., see Simonovitch, S. (3) 915–927
Irish, M., see Kumfor, F. (1) 237–248
Irwin, M.G., see Huang, C. (1) 213–226
Ishiguro, K., see Elahi, M. (4) 1209–1224
Itzhaki, R.F., R. Lathe, B.J. Balin, M.J. Ball, E.L. Bearer, H. Braak, M.J. Bullido, C. Carter, M. Clerici, S.L. Cosby, K.D. Tredici, H. Field, T. Fulop, C. Grassi, W.S.T. Griffin, J. Haas, A.P. Hudson, A.R. Kamer, D.B. Kell, F. Licastro, L. Letenneur, H. Lövheim, R. Mancuso, J. Miklossy, C. Otth, A.T. Palamara, G. Perry, C. Preston, E. Pretorius, T. Strandberg, N. Tabet, S.D. Taylor-Robinson and J.A. Whittum-Hudson, Microbes and Alzheimer’s Disease (4) 979–984
Jabłoński, M., see Pluta, R. (4) 1023–1031
Jackson, N., see Pasquier, F. (4) 1131–1143
Jacques, P.F., see Karakis, I. (2) 451–461
Jan, M., see Grangeon, L. (3) 905–913
Jang, H.Y., see Kim, Y. (4) 1057–1068
Januszewski, S., see Pluta, R. (4) 1023–1031
Jia, J.-P., see Wang, H.-F. (1) 227–236
Jiang, G.-X., see Yao, Q. (4) 1175–1182
Jiang, T., see Wang, H.-F. (1) 227–236
Jiskoot, L.C., see Louwersheimer, E. (2) 581–590
Joannette, M., see Lavallée, M.M. (4) 1225–1236
Jögi, J., see Smith, R. (2) 339–343
Jones, I.R., see Clare, L. (1) 139–150
Joubert, S., see Lavallée, M.M. (4) 1225–1236
Joyce, J.A., see Stern, R.A. (4) 1099–1109
Jung, B., see Bousiges, O. (4) 1069–1083
Jung, M., see Song, J.M., (2) 591–604
Junot, C., see Barthélemy, N.R. (4) 1033–1043
Kai-Hui Yeo, H., see Chai, Y.L. (4) 1111–1118
Kakuma, T., see Kida, J. (2) 405–415
Kamer, A.R., see Itzhaki, R.F. (4) 979–984
Karakis, I., M.P. Pase, A. Beiser, S.L. Booth, P.F. Jacques, G. Rogers, C. DeCarli, R.S. Vasan, T.J. Wang, J.J. Himali, C. Annweiler and S. Seshadri, Association of Serum Vitamin D with the Risk of Incident Dementia and Sub-clinical Indices of Brain Aging: The Framingham Heart Study (2) 451–461
Kas, A., see Migliaccio, R. (4) 1119–1130
Kato, M., see Sakai, K. (4) 997–1002
Kawaguchi, K., see Sakai, K. (4) 997–1002
Kawamoto, C., see Gray, N.E. (2) 391–403
Kay, J., see Nunez, K. (1) 151–163
Kell, D.B., see Itzhaki, R.F. (4) 979–984
Kemppainen, S., see Guillot, F. (4) 1157–1173
Kepp, T., see Suppa, P. (3) 867–873
Kergoat, M.-J., see Lavallée, M.M. (4) 1225–1236
Kerssens, C.J., see Gossink, F.T. (4) 1249–1256
Kerti, L., see Külzow, N. (3) 713–725
Kesavalu, L., see Singhrao, S.K. (4) 935–948
Ketter, N., see Pasquier, F. (4) 1131–1143
Keulen, M.A., see Louwersheimer, E. (2) 581–590
Kida, J., K. Nemoto, C. Ikejima, S. Bun, T. Kakuma, K. Mizukami and T. Asada, Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer’s Disease: A Community-Based Longitudinal Study (2) 405–415
Kilimann, I., see Eichler, T. (3) 847–855
Kim, C., see Kim, Y. (4) 1057–1068
Kim, J., see Song, J.M., (2) 591–604
Kim, Y., C. Kim, H.Y. Jang and I. Mook-Jung, Inhibition of Cholesterol Biosynthesis Reduces γ-Secretase Activity and Amyloid-β Generation (4) 1057–1068
Kim, Y.H., S.H. Beak, A. Charidimou and M. Song, Discovering New Genes in the Pathways of Common Sporadic Neurodegenerative Diseases: A Bioinformatics Approach (1) 293–312
Kim, Y.J., see Lyoo, C.H. (3) 671–675
Kitaguchi, N., see Sakai, K. (4) 997–1002
Kizek, R., see Adam, P. (3) 637–656
Kocki, J., see Pluta, R. (4) 1023–1031
Kook, S.Y., see Son, S.M. (4) 1197–1208
Křížková, S., see Adam, P. (3) 637–656
Krishna, K., T. Behnisch and S. Sajikumar, Inhibition of Histone Deacetylase 3 Restores Amy-loid-β Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons (3) 783–791
Krotow, A., see Nunez, K. (1) 151–163
Krudop, W.A., see Gossink, F.T. (4) 1249–1256
Kuai, X.-x., see Yang, C.-c. (1) 33–44
Kucera, M., see Dingova, D. (3) 801–813
Külzow, N., A.V. Witte, L. Kerti, U. Grittner, J.P. Schuchardt, A. Hahn and A. Flöel, Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults (3) 713–725
Kumfor, F., D. Teo, L. Miller, S. Lah, E. Mioshi, J.R. Hodges, O. Piguet and M. Irish, Examining the Relationship Between Autobiographical Memory Impairment and Carer Burden in Dementia Syndromes (1) 237–248
Kuo, S.-H., see Wang, H.-L. (1) 45–55
Kuppusamy, P., see Fang, D. (2) 571–580
Kuroda, M., see Sakai, K. (4) 997–1002
Kurz, A., see Pasquini, L. (1) 313–326
Lacomblez, L., see Migliaccio, R. (4) 1119–1130
Lacorte, E., see Grande, G. (1) 57–67
Lacritz, L.H., see LoBue, C. (3) 727–736
Lah, S., see Kumfor, F. (1) 237–248
Lanctôt, K.L., see Chau, S.A. (3) 837–846
Lane, K.A., see Rattanabannakit, C. (4) 1145–1155
Lange, C., see Suppa, P. (3) 867–873
Laplanche, J.-L., see Grangeon, L. (3) 905–913
Laroche, S., see Guillot, F. (4) 1157–1173
Larsen, D., see Remington, R. (4) 991–995
Lathe, R., see Itzhaki, R.F. (4) 979–984
Lauriola, M., see D’Onofrio, G. (2) 427–437
Lavallée, M.M., D. Gandini, I. Rouleau, G.T. Vallet, M. Joannette, M.-J. Kergoat, T. Busigny, B. Rossion and S. Joubert, A Qualitative Impairment in Face Perception in Alzheimer’s Disease: Evidence from a Reduced Face Inversion Effect (4) 1225–1236
Lavasseur, G., see Guillot, F. (4) 1157–1173
Lavaux, T., see Bousiges, O. (4) 1069–1083
Lee, M.S., see Lyoo, C.H. (3) 671–675
Lefaucheur, R., see Grangeon, L. (3) 905–913
Lehericy, S., see Migliaccio, R. (4) 1119–1130
Lehmann, S., see Barthélemy, N.R. (4) 1033–1043
Leinonen, H., A. Lipponen, K. Gurevicius and H. Tanila, Normal Amplitude of Electroretinography and Visual Evoked Potential Responses in AβPP/PS1 Mice (1) 21–26
Letenneur, L., see Itzhaki, R.F. (4) 979–984
Leterme, G.L.P., see Pasquier, F. (4) 1131–1143
Leyton, C.E., see Ramanan, S. (2) 367–376
Leyton, C.E., see Schubert, S. (3) 775–782
Li, G.-H., see Li, W.-X. (2) 417–425
Li, H., see Fang, D. (2) 571–580
Li, L., see Yang, C.-c. (1) 33–44
Li, R., see Xu, L. (4) 1045–1056
Li, W.-X., S.-X. Dai, J.-Q. Liu, Q. Wang, G.-H. Li and J.-F. Huang, Integrated Analysis of Alzheimer’s Disease and Schizophrenia Dataset Revealed Different Expression Pattern in Learning and Memory (2) 417–425
Li, Y., see Chang, L. (1) 197–212
Licastro, F., see Itzhaki, R.F. (4) 979–984
Liepelt-Scarfone, I., see Pilotto, A. (2) 563–570
Li-Hsian Chen, C., see Chai, Y.L. (4) 1111–1118
Lin, Y., see Florian, H. (4) 1237–1247
Lipponen, A., see Leinonen, H. (1) 21–26
Lipschitz, S., see Florian, H. (4) 1237–1247
Liu, E., see Pasquier, F. (4) 1131–1143
Liu, J., see Chang, L. (1) 197–212
Liu, J.-Q., see Li, W.-X. (2) 417–425
Liu, N., see Wang, H.-L. (1) 45–55
Liu, X.-G., see Wang, H.-L. (1) 45–55
Liu, Y., see Wang, H.-F. (1) 227–236
Lladó, A., see Sánchez-Valle, R. (3) 827–835
Lo Faro, M., see Costassa, E.V. (3) 875–887
LoBue, C., D. Denney, L.S. Hynan, H.C. Rossetti, L.H. Lacritz, J. Hart Jr., K.B. Womack, F.L. Woon and C.M. Cul-lum, Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis (3) 727–736
Long, Z., see Xu, L. (4) 1045–1056
López, F.J.G., see de Pedro-Cuesta, J. (4) 1003–1022
López-Ramos, J.C., see Manso, Y. (1) 81–95
Lou, G., Q. Zhang, F. Xiao, Q. Xiang, Z. Su and Y. Huang, Intranasal TAT-haFGF Improves Cognition and Amyloid-β Pathology in an AβPP/PS1 Mouse Model of Alzheimer’s Disease (4) 985–990
Louwersheimer, E., M.A. Keulen, M.D. Steenwijk, M.P. Wattjes, L.C. Jiskoot, H. Vrenken, C.E. Teunissen, B.N.M. van Berckel, W.M. van der Flier, P. Scheltens, J.C. van Swieten and Y.A.L. Pijnenburg, Heterogeneous Lan-guage Profiles in Patients with Primary Progressive Aphasia due to Alzheimer’s Disease (2) 581–590
Lövheim, H., see Itzhaki, R.F. (4) 979–984
Luchsinger, J.A., T. Perez, H. Chang, P. Mehta, J. Steffener, G. Pradabhan, M. Ichise, J. Manly, D.P. Devanand and E. Bagiella, Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Con-trolled Clinical Trial (2) 501–514
Lv, A., see Chang, L. (1) 197–212
Lyoo, C.H., H. Cho, J.Y. Choi, M.S. Hwang, S.K. Hong, Y.J. Kim, Y.H. Ryu and M.S. Lee, Tau Accumulation in Primary Motor Cortex of Variant Alzheimer’s Disease with Spastic Paraparesis (3) 671–675
Maarouf, C.L., see Dugger, B.N. (2) 345–356
Machan, J.T., see Masoud, A.M. (4) 1257–1264
Maggiore, L., see Grande, G. (1) 57–67
Magoni, M., see Premi, E. (1) 249–262
Makovac, E., see Serra, L. (2) 377–389
Maldonado, R., see Aso, E. (2) 489–500
Maletta, R., see Montesanto, A. (4) 1265–1274
Maltête, D., see Grangeon, L. (3) 905–913
Mancuso, R., see Itzhaki, R.F. (4) 979–984
Mangiacotti, A., see D’Onofrio, G. (2) 427–437
Manly, J., see Luchsinger, J.A. (2) 501–514
Manousopoulou, A., S. Saito, Y. Yamamoto, N.M. Al-Daghri, M. Ihara, R.O. Carare and S.D. Garbis, Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer’s Disease Mouse Model (2) 333–338
Manso, Y., G. Comes, J.C. López-Ramos, M. Belfiore, A. Molinero, M. Giralt, J. Carrasco, P.A. Adlard, A.I. Bush, J.M. Delgado-García and J. Hidalgo, Overexpression of Metallothionein-1 Modulates the Pheno-type of the Tg2576 Mouse Model of Alzheimer’s Disease (1) 81–95
Marchi, M., see Caffarra, P. (1) 27–31
Mariani, C., see Grande, G. (1) 57–67
Marra, C., see Bocchetta, M. (1) 277–291
Marra, C., see Serra, L. (2) 377–389
Marshall, C., see Xu, Z.-Q. (1) 179–195
Martin, B.M., see Stern, R.A. (4) 1099–1109
Martin, J.-J., see Niemantsverdriet, E. (1) 97–106
Martinaud, O., see Grangeon, L. (3) 905–913
Martínez-Martín, P., see de Pedro-Cuesta, J. (4) 1003–1022
Martin-Hunyadi, C., see Bousiges, O. (4) 1069–1083
Mas-Bargues, C., see Bonet-Costa, V. (3) 701–711
Masliah, E., see Simonovitch, S. (3) 915–927
Masoud, A.M., S.W. Bihaqi, J.T. Machan, N.H. Zawia and W.E. Renehan, Early-Life Exposure to Lead (Pb) Alters the Expression of microRNA that Target Proteins Associated with Alzheimer’s Disease (4) 1257–1264
Mastropasqua, C., see Serra, L. (2) 377–389
Masullo, C., see Bocchetta, M. (1) 277–291
Matsumoto, S.-E., see Elahi, M. (4) 1209–1224
Mattek, N., see Nishihira, J. (3) 857–866
Maurella, C., see Costassa, E.V. (3) 875–887
McCrone, P., see Abdin, E. (2) 439–449
McDonald, B.C., see Rattanabannakit, C. (4) 1145–1155
Medrano, M.-J., see de Pedro-Cuesta, J. (4) 1003–1022
Meechoovet, B., see Dugger, B.N. (2) 345–356
Mega, A., see Bocchetta, M. (1) 277–291
Mehta, P., see Luchsinger, J.A. (2) 501–514
Meier, A., see Florian, H. (4) 1237–1247
Meloni, D., see Costassa, E.V. (3) 875–887
Messier, C., see Granger, M.W. (3) 757–773
Meyer, M.-E., see Andriuta, D. (3) 793–800
Michaelson, D.M., see Simonovitch, S. (3) 915–927
Michalowsky, B., see Eichler, T. (3) 847–855
Michon, A., see Migliaccio, R. (4) 1119–1130
Miettinen, P.O., see Guillot, F. (4) 1157–1173
Migliaccio, R., C. Gallea, A. Kas, V. Perlbarg, D. Samri, L. Trotta, A. Michon, L. Lacomblez, B. Dubois, S. Lehericy and P. Bartolomeo, Functional Connectivity of Ventral and Dorsal Visual Streams in Posterior Cortical Atrophy (4) 1119–1130
Miklossy, J., see Itzhaki, R.F. (4) 979–984
Miller, L., see Kumfor, F. (1) 237–248
Miñarro, J., see Bonet-Costa, V. (3) 701–711
Mioshi, E., see Kumfor, F. (1) 237–248
Mitchell, A.J., see Benito-León, J. (2) 533–544
Mizukami, K., see Kida, J. (2) 405–415
Moffat, E., see Song, J.M., (2) 591–604
Molinero, A., see Manso, Y. (1) 81–95
Molinuevo, J.L. see Sánchez-Valle, R. (3) 827–835
Molloy, D.W., see O’Caoimh, R. (2) 619–629
Monté, G.C., see Sánchez-Valle, R. (3) 827–835
Montesanto, A., P. Crocco, M. Anfossi, N. Smirne, G. Puccio, R. Colao, R. Maletta, G. Passarino, A.C. Bruni and G. Rose, The Genetic Variability of UCP4 Affects the Individual Susceptibility to Late-Onset Alzheimer’s Disease and Modifies the Disease’s Risk in APOE-ɛ4 Carriers (4) 1265–1274
Mook-Jung, I., see Kim, Y. (4) 1057–1068
Mook-Jung, I., see Son, S.M. (4) 1197–1208
Moon, M., see Son, S.M. (4) 1197–1208
Moon, W.-J., see Moon, Y. (3) 737–745
Moon, Y., S.-H. Han and W.-J. Moon, Patterns of Brain Iron Accumulation in Vascular Dementia and Alz-heimer’s Dementia Using Quantitative Susceptibility Mapping Imaging (3) 737–745
Morin, J.-P., G. Cerón-Solano, G. Velázquez-Campos, G. Pacheco-López, F. Bermúdez-Rattoni and S. Díaz-Cintra, Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer’s Disease (1) 69–79
Morrell, C., see Remington, R. (4) 991–995
Motoi, Y., see Elahi, M. (4) 1209–1224
Moullart, V., see Andriuta, D. (3) 793–800
Müller, M.J., see Heßmann, P. (2) 545–561
Myers, N.E., see Pasquini, L. (1) 313–326
Nacmias, B., see Bocchetta, M. (1) 277–291
Nakai, S., see Sakai, K. (4) 997–1002
Nakanishi, M., T. Nakashima, Y. Shindo, J. Niimura and A. Nishida, Japanese Care Location and Medical Proce-dures for People with Dementia in the Last Month of Life (3) 747–755
Nakashima, T., see Nakanishi, M. (3) 747–755
Nam, J.H., see Song, J.M., (2) 591–604
Nemoto, K., see Kida, J. (2) 405–415
Newson, M., see Haworth, J. (1) 263–275
Ng, L.L., see Abdin, E. (2) 439–449
Nicolakakis, N., see Ongali, B. (4) 1183–1195
Nicolas, G., see Grangeon, L. (3) 905–913
Niemantsverdriet, E., J. Goossens, H. Struyfs, J.-J. Martin, J. Goeman, P.P. De Deyn, H. Vanderstichele and S. En-gelborghs, Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alz-heimer’s Disease (1) 97–106
Niimura, J., see Nakanishi, M. (3) 747–755
Ninan, S., see Femminella, G.D. (4) 1275–1289
Nishida, A., see Nakanishi, M. (3) 747–755
Nishihira, J., T. Tokashiki, Y. Higashiuesato, D.C. Willcox, N. Mattek, L. Shinto, Y. Ohya and H.H. Dodge, Associ-ations between Serum Omega-3 Fatty Acid Levels and Cognitive Functions among Community-Dwelling Oc-togenarians in Okinawa, Japan: The KOCOA Study (3) 857–866
Nunez, K., J. Kay, A. Krotow, M. Tong, A.R. Agarwal, E. Cadenas and S.M. de la Monte, Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Rel-evance to Alzheimer’s Disease (1) 151–163
O’Caoimh, R., S. Timmons and D.W. Molloy, Screening for Mild Cognitive Impairment: Comparison of “MCI Specific” Screening Instruments (2) 619–629
Ohlenbusch, A., see Stoeck, K. (3) 683–687
Ohya, Y., see Nishihira, J. (3) 857–866
Okuliarova, P., see Dingova, D. (3) 801–813
Olsen, I., see Singhrao, S.K. (4) 935–948
Olsson, T., see Smith, R. (2) 339–343
Ongali, B., N. Nicolakakis, X.-K. Tong, T. Aboulkassim, H. Imboden and E. Hamel, Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer’s Disease (4) 1183–1195
Opazo, C., see Peters, C. (3) 689–699
Ortner, M., see Pasquini, L. (1) 313–326
Othman, A.A., see Florian, H. (4) 1237–1247
Otth, C., see Itzhaki, R.F. (4) 979–984
Pacheco-López, G., see Morin, J.-P. (1) 69–79
Paciello, O., see Costassa, E.V. (3) 875–887
Padovani, A. see Premi, E. (1) 249–262
Padovani, A., see Bocchetta, M. (1) 277–291
Padovani, A., see Pilotto, A. (2) 563–570
Page, R., see Remington, R. (4) 991–995
Pak, D.T.S., see Song, J.M., (2) 591–604
Palamara, A.T., see Itzhaki, R.F. (4) 979–984
Paleacu, D., see Shelef, A. (1) 15–19
Panegyres, P.K., see Chen, H.-Y. (2) 515–523
Pang, S., see Abdin, E. (2) 439–449
Panza, F., see D’Onofrio, G. (2) 427–437
Paquet, C., see Grangeon, L. (3) 905–913
Paris, F.F., see D’Onofrio, G. (2) 427–437
Parnetti, L., see Bocchetta, M. (1) 277–291
Paroni, G.H., see D’Onofrio, G. (2) 427–437
Pase, M.P., see Karakis, I. (2) 451–461
Pasquier, F., C. Sadowsky, A. Holstein, G.L.P. Leterme, Y. Peng, N. Jackson, N.C. Fox, N. Ketter, E. Liu, J.M. Ryan and for the ACC-001 (QS-21) Study Team, Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease (4) 1131–1143
Pasquier, F., see Grangeon, L. (3) 905–913
Pasquini, L., M. Scherr, M. Tahmasian, N.E. Myers, M. Ortner, A. Kurz, H. Förstl, C. Zimmer, T. Grimmer, A. Akhrif, A.M. Wohlschläger, V. Riedl and C. Sorg, Increased Intrinsic Activity of Medial-Temporal Lobe Subregions is Associated with Decreased Cortical Thickness of Medial-Parietal Areas in Patients with Alzheimer’s Disease Dementia (1) 313–326
Passarino, G., see Montesanto, A. (4) 1265–1274
Peck, K.J., T.A. Girard, F.A. Russo and A.J. Fiocco, Music and Memory in Alzheimer’s Disease and The Potential Underlying Mechanisms (4) 949–959
Pekařík, V., see Adam, P. (3) 637–656
Peletto, S., see Costassa, E.V. (3) 875–887
Peng, Y., see Pasquier, F. (4) 1131–1143
Peoc’h, K., see Grangeon, L. (3) 905–913
Pere, J.-J., see Godefroy, O. (3) 815–825
Perez, T., see Luchsinger, J.A. (2) 501–514
Perlbarg, V., see Migliaccio, R. (4) 1119–1130
Perreau, V.M., see Xu, H. (2) 471–487
Perry, G., see Itzhaki, R.F. (4) 979–984
Peters, C., D. Bascuñán, C. Opazo and L.G. Aguayo, Differential Membrane Toxicity of Amy-loid-β Fragments by Pore Forming Mechanisms (3) 689–699
Petniak, A., see Pluta, R. (4) 1023–1031
Philippi, N., see Bousiges, O. (4) 1069–1083
Phillips, M., see Haworth, J. (1) 263–275
Piaceri, I., see Bocchetta, M. (1) 277–291
Picco, L., see Abdin, E. (2) 439–449
Pievani, M., see Bocchetta, M. (1) 277–291
Piguet, O., see Kumfor, F. (1) 237–248
Piguet, O., see Schubert, S. (3) 775–782
Piguet, O., see Wong, S. (3) 889–903
Pijnenburg, Y.A.L., see Gossink, F.T. (4) 1249–1256
Pijnenburg, Y.A.L., see Louwersheimer, E. (2) 581–590
Pilotto, A., R. Turrone, I. Liepelt-Scarfone, M. Bianchi, L. Poli, B. Borroni, A. Alberici, E. Premi, A. Formenti, B. Bigni, M. Cosseddu, E. Cottini, D. Berg and A. Padovani, Vascular Risk Factors and Cognition in Parkinson’s Disease (2) 563–570
Pinkas-Kramarski, R., see Simonovitch, S. (3) 915–927
Plopsky, I., see Shelef, A. (1) 15–19
Pluta, R., J. Kocki, M. Ułamek-Kozioł, A. Petniak, P. Gil-Kulik, S. Januszewski, J. Bogucki, M. Jabłoński, J. Brzozowska, W. Furmaga-Jabłońska, A. Bogucka-Kocka and S.J. Czuczwar, Discrepancy in Expression of β-Secretase and Amyloid-β Protein Precursor in Alzheimer-Related Genes in the Rat Medial Temporal Lobe Cortex Following Transient Global Brain Ischemia (4) 1023–1031
Poli, L., see Pilotto, A. (2) 563–570
Pomati, S., see Grande, G. (1) 57–67
Porteri, C., see Bocchetta, M. (1) 277–291
Pradabhan, G., see Luchsinger, J.A. (2) 501–514
Premi, E., F. Cauda, T. Costa, M. Diano, S. Gazzina, V. Gualeni, A. Alberici, S. Archetti, M. Magoni, R. Gasparotti, A. Padovani and B. Borroni, Looking for Neuroimaging Markers in Frontotemporal Lobar Degeneration Clinical Trials: A Multi-Voxel Pattern Analysis Study in Granulin Disease (1) 249–262
Premi, E., see Pilotto, A. (2) 563–570
Preston, C., see Itzhaki, R.F. (4) 979–984
Pretorius, E., see Itzhaki, R.F. (4) 979–984
Prickaerts, J., see Sierksma, A.S.R. (3) 677–682
Prince, M., see Abdin, E. (2) 439–449
Prins, N.D., see Gossink, F.T. (4) 1249–1256
Psychogios, M.N., see Stoeck, K. (3) 683–687
Puccio, G., see Montesanto, A. (4) 1265–1274
Quillard-Muraine, M., see Grangeon, L. (3) 905–913
Quinn, C., see Clare, L. (1) 139–150
Quinn, J.F., see Gray, N.E. (2) 391–403
Rábano, A., see de Pedro-Cuesta, J. (4) 1003–1022
Rabinovici, G.D., see Smith, R. (2) 339–343
Racine, E., C. Forlini, J. Aspler and J. Chandler, Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimer’s Disease: Opening the Conversation to Prepare Ethical Responses (1) 1–9
Rainero, I., see Bocchetta, M. (1) 277–291
Ramanan, S., E. Flanagan, C.E. Leyton, V.L. Villemagne, C.C. Rowe, J.R. Hodges and M. Hornberger, Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pa-thology (2) 367–376
Rattanabannakit, C., S.L. Risacher, S. Gao, K.A. Lane, S.A. Brown, B.C. McDonald, F.W. Unverzagt, L.G. Apostolova, A.J. Saykin and M.R. Farlow, The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests (4) 1145–1155
Redaelli, V., see Bocchetta, M. (1) 277–291
Reese, J.P., see Heßmann, P. (2) 545–561
Reiman, E.M., see Dugger, B.N. (2) 345–356
Remington, R., C. Bechtel, D. Larsen, A. Samar, R. Page, C. Morrell and T.B. Shea, Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer’s Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study (4) 991–995
Renehan, W.E., see Masoud, A.M. (4) 1257–1264
Reñé-Ramírez, R., see Turró-Garriga, O. (2) 357–366
Richter, S., see Eichler, T. (3) 847–855
Riedl, V., see Pasquini, L. (1) 313–326
Risacher, S.L., see Rattanabannakit, C. (4) 1145–1155
Robieson, W.Z., see Florian, H. (4) 1237–1247
Robillard, J.M., The Online Environment: A Key Variable in the Ethical Response to Complementary and Alternative Medicine for Alzheimer’s Disease (1) 11–13
Rodriguez-Arias, M., see Bonet-Costa, V. (3) 701–711
Rogers, G., see Karakis, I. (2) 451–461
Rogers, P.J., see Haworth, J. (1) 263–275
Roher, A.E., see Dugger, B.N. (2) 345–356
Rose, G., see Montesanto, A. (4) 1265–1274
Rossetti, H.C., see LoBue, C. (3) 727–736
Rossi, G., see Bocchetta, M. (1) 277–291
Rossion, B., see Lavallée, M.M. (4) 1225–1236
Rouleau, I., see Lavallée, M.M. (4) 1225–1236
Roussel, M., see Godefroy, O. (3) 815–825
Rowe, C.C., see Ramanan, S. (2) 367–376
Ruffini, L., see Caffarra, P. (1) 27–31
Ruiz-Tovar, M., see de Pedro-Cuesta, J. (4) 1003–1022
Russo, F.A., see Peck, K.J. (4) 949–959
Rutten, B.P.F., see Sierksma, A.S.R. (3) 677–682
Ryan, J.M., see Pasquier, F. (4) 1131–1143
Ryu, Y.H., see Lyoo, C.H. (3) 671–675
Sadowsky, C., see Pasquier, F. (4) 1131–1143
Saito, S., see Manousopoulou, A. (2) 333–338
Sajikumar, S., see Krishna, K. (3) 783–791
Sakai, K., T. Senda, R. Hata, M. Kuroda, M. Hasegawa, M. Kato, M. Abe, K. Kawaguchi, S. Nakai, Y. Hiki, Y. Yuzawa and N. Kitaguchi, Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer’s Disease by Removal of Blood Amyloid (4) 997–1002
Sala-Llonch, R., see Sánchez-Valle, R. (3) 827–835
Samar, A., see Remington, R. (4) 991–995
Sambasivam, R., see Abdin, E. (2) 439–449
Samri, D., see Migliaccio, R. (4) 1119–1130
Sancarlo, D., see D’Onofrio, G. (2) 427–437
Sánchez-Valle, R., G.C. Monté, R. Sala-Llonch, B. Bosch, J. Fortea, A. Lladó, A. Antonell, M. Balasa, N. Bargalló and J.L. Molinuevo, White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer’s Disease (3) 827–835
Savage, G., see Wong, S. (3) 889–903
Saykin, A.J., see Rattanabannakit, C. (4) 1145–1155
Scarpini, E., see Bocchetta, M. (1) 277–291
Scarpini, E., see Grande, G. (1) 57–67
Scheltens, P., see Gossink, F.T. (4) 1249–1256
Scheltens, P., see Louwersheimer, E. (2) 581–590
Scherr, M., see Pasquini, L. (1) 313–326
Scherzer-Attali, R., see Frenkel-Pinter, M. (1) 165–178
Schilling, M.A., Unraveling Alzheimer’s: Making Sense of the Relationship between Diabetes and Alzheimer’s Disease (4) 961–977
Schmidt, J., see Stoeck, K. (3) 683–687
Schmukler, E., see Simonovitch, S. (3) 915–927
Schraen, S., see Andriuta, D. (3) 793–800
Schraen-Maschke, S., see Barthélemy, N.R. (4) 1033–1043
Schubert, S., C.E. Leyton, J.R. Hodges and O. Piguet, Longitudinal Memory Profiles in Behavioral-Variant Fronto-temporal Dementia and Alzheimer’s Disease (3) 775–782
Schuchardt, J.P., see Külzow, N. (3) 713–725
Seeberg, G., see Heßmann, P. (2) 545–561
Segal, D., see Frenkel-Pinter, M. (1) 165–178
Senda, T., see Sakai, K. (4) 997–1002
Sergeant, N., see Barthélemy, N.R. (4) 1033–1043
Seripa, D., see D’Onofrio, G. (2) 427–437
Serra, L., M. Cercignani, C. Mastropasqua, M. Torso, B. Spanò, E. Makovac, V. Viola, G. Giulietti, C. Marra, C. Caltagirone and M. Bozzali, Longitudinal Changes in Functional Brain Connectivity Predicts Conversion to Alzheimer’s Disease (2) 377–389
Seshadri, S., see Karakis, I. (2) 451–461
Shah, S., see Stern, R.A. (4) 1099–1109
Shaw, L.M., see White, M.T. (2) 463–470
Shea, T.B., see Remington, R. (4) 991–995
Shelef, A., Y. Barak, U. Berger, D. Paleacu, S. Tadger, I. Plopsky and Y. Baruch, Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study (1) 15–19
Shen, F., see Hong, X.-P. (2) 605–617
ShiDu Yan, S., see Fang, D. (2) 571–580
Shin, H.-J., see Son, S.M. (4) 1197–1208
Shindo, Y., see Nakanishi, M. (3) 747–755
Shinto, L., see Nishihira, J. (3) 857–866
Sierksma, A.S.R., L. de Nijs, G. Hoogland, T. Vanmierlo, F.W. van Leeuwen, B.P.F. Rutten, H.W.M. Steinbusch, J. Prickaerts and D.L.A. van den Hove, Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice (3) 677–682
Sikkes, S.A., see Gossink, F.T. (4) 1249–1256
Silani, V., see Bocchetta, M. (1) 277–291
Simonovitch, S., E. Schmukler, A. Bespalko, T. Iram, D. Frenkel, D.M. Holtzman, E. Masliah, D.M. Michaelson and R. Pinkas-Kramarski, Impaired Autophagy in APOE4 Astrocytes (3) 915–927
SINdem, see Bocchetta, M. (1) 277–291
Singh, N., see Tripathi, A.K. (1) 107–121
Singhrao, S.K., A. Harding, S. Chukkapalli, I. Olsen, L. Kesavalu and S. Crean, Apolipoprotein E Related Co-Morbidities and Alzheimer’s Disease (4) 935–948
Small, D.H., see Southam, K.A. (3) 657–669
Smirne, N., see Montesanto, A. (4) 1265–1274
Smith, R., M. Wibom, T. Olsson, D. Hägerström, J. Jögi, G.D. Rabinovici and O. Hansson, Poste-rior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer’s Disease Pa-tient with Presenilin-1 Mutation (2) 339–343
Son, S.M., H.-J. Shin, J. Byun, S.Y. Kook, M. Moon, Y.J. Chang and I. Mook-Jung, Metformin Facilitates Amyloid-β Generation by β- and γ-Secretases via Autophagy Activation (4) 1197–1208
Song, J.M., Y.M. Sung, J.H. Nam, H. Yoon, A. Chung, E. Moffat, M. Jung, D.T.S. Pak, J. Kim and H.-S. Hoe, A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway (2) 591–604
Song, M., see Kim, Y.H. (1) 293–312
Song, Q.-Y., see Wang, H.-L. (1) 45–55
Song, Y., see Chang, L. (1) 197–212
Sorbi, S., see Bocchetta, M. (1) 277–291
Sorg, C., see Pasquini, L. (1) 313–326
Sorrentino, G., see Bocchetta, M. (1) 277–291
Southam, K.A., A.J. Vincent and D.H. Small, Do Microglia Default on Network Maintenance in Alzheimer’s Disease? (3) 657–669
Spallazzi, M., see Caffarra, P. (1) 27–31
Spanò, B., see Serra, L. (2) 377–389
Spies, L., see Suppa, P. (3) 867–873
Spotti, A., see Caffarra, P. (1) 27–31
St. George-Hyslop, P., see Granger, M.W. (3) 757–773
Steenwijk, M.D., see Louwersheimer, E. (2) 581–590
Steffener, J., see Luchsinger, J.A. (2) 501–514
Steinbusch, H.W.M., see Sierksma, A.S.R. (3) 677–682
Steinfeld, R., see Stoeck, K. (3) 683–687
Stek, M.L., see Gossink, F.T. (4) 1249–1256
Stern, R.A., Y. Tripodis, C.M. Baugh, N.G. Fritts, B.M. Martin, C. Chaisson, R.C. Cantu, J.A. Joyce, S. Shah, T. Ikezu, J. Zhang, C. Gercel-Taylor and D.D. Taylor, Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy (4) 1099–1109
Stoeck, K., M.N. Psychogios, A. Ohlenbusch, R. Steinfeld and J. Schmidt, Late-Onset Metachromatic Leukodystro-phy with Early Onset Dementia Associated with a Novel Missense Mutation in the Arylsulfatase A Gene (3) 683–687
Strandberg, T., see Itzhaki, R.F. (4) 979–984
Strbova, J., see Dingova, D. (3) 801–813
Struyfs, H., see Niemantsverdriet, E. (1) 97–106
Su, Y., see Chu, S. (2) 525–532
Su, Z., see Lou, G. (4) 985–990
Suardi, S., see Bocchetta, M. (1) 277–291
Subramaniam, M., see Abdin, E. (2) 439–449
Sue, L.I., see Dugger, B.N. (2) 345–356
Sung, Y.M., see Song, J.M., (2) 591–604
Suppa, P., H. Hampel, T. Kepp, C. Lange, L. Spies, J.B. Fiebach, B. Dubois and R. Buchert for the Alz-heimer’s Disease Neuroimaging Initiative, Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer’s Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Im-pairment (3) 867–873
Tabet, N., see Itzhaki, R.F. (4) 979–984
Tadger, S., see Shelef, A. (1) 15–19
Tagliavini, F., see Bocchetta, M. (1) 277–291
Tagliavini, F., see Costassa, E.V. (3) 875–887
Tahmasian, M., see Pasquini, L. (1) 313–326
Tal, S., see Frenkel-Pinter, M. (1) 165–178
Tales, A., see Haworth, J. (1) 263–275
Tan, L., see Wang, H.-F. (1) 227–236
Tan, M.-S., see Wang, H.-F. (1) 227–236
Tang, Q., see Florian, H. (4) 1237–1247
Tanila, H., see Guillot, F. (4) 1157–1173
Tanila, H., see Leinonen, H. (1) 21–26
Taylor, D.D., see Stern, R.A. (4) 1099–1109
Taylor, M.W., see Granger, M.W. (3) 757–773
Taylor-Robinson, S.D., see Itzhaki, R.F. (4) 979–984
Teipel, S., see Eichler, T. (3) 847–855
Teo, D., see Kumfor, F. (1) 237–248
Teunissen, C.E., see Louwersheimer, E. (2) 581–590
Thyrian, J.R., see Eichler, T. (3) 847–855
Timmons, S., see O’Caoimh, R. (2) 619–629
Tin-Chun Wong, G., see Huang, C. (1) 213–226
Tokashiki, T., see Nishihira, J. (3) 857–866
Tong, M., C. Deochand, J. Didsbury and S.M. de la Monte, T3D-959: A Multi-Faceted Disease Remedial Drug Can-didate for the Treatment of Alzheimer’s Disease (1) 123–138
Tong, M., see Nunez, K. (1) 151–163
Tong, X.-K., see Ongali, B. (4) 1183–1195
Tonoli, E., see Costassa, E.V. (3) 875–887
Torrens-Burton, A., see Haworth, J. (1) 263–275
Torso, M., see Serra, L. (2) 377–389
Tredici, K.D., see Itzhaki, R.F. (4) 979–984
Tripathi, A.K. and N. Singh, Prion Protein-Hemin Interaction Upregulates Hemoglobin Synthesis: Implications for Cerebral Hemorrhage and Sporadic Creutzfeldt-Jakob Disease (1) 107–121
Tripodis, Y., see Stern, R.A. (4) 1099–1109
Trotta, L., see Migliaccio, R. (4) 1119–1130
Tsai, R.M., see Wang, H.-F. (1) 227–236
Tsz-Wa Ng, O., see Huang, C. (1) 213–226
Turró-Garriga, O., J. Garre-Olmo, L. Calvó-Perxas, R. Reñé-Ramírez, J. Gascón-Bayarri and J.L. Conde-Sala, Course and Determinants of Anosognosia in Alzheimer’s Disease: A 12-Month Follow-up (2) 357–366
Turrone, R., see Pilotto, A. (2) 563–570Ułamek-Kozioł, M., see Pluta, R. (4) 1023–1031
Unverzagt, F.W., see Rattanabannakit, C. (4) 1145–1155
Vaculovičová, M., see Adam, P. (3) 637–656
Vaingankar, J.A., see Abdin, E. (2) 439–449
Vallet, G.T., see Lavallée, M.M. (4) 1225–1236
van Berckel, B.N.M., see Louwersheimer, E. (2) 581–590
van den Hove, D.L.A., see Sierksma, A.S.R. (3) 677–682
van der Flier, W.M., see Louwersheimer, E. (2) 581–590
van Leeuwen, F.W., see Sierksma, A.S.R. (3) 677–682
van Swieten, J.C., see Louwersheimer, E. (2) 581–590
Vanacore, N., see Grande, G. (1) 57–67
Vanderstichele, H., see Niemantsverdriet, E. (1) 97–106
Vanmierlo, T., see Sierksma, A.S.R. (3) 677–682
Vasan, R.S., see Karakis, I. (2) 451–461
Velázquez-Campos, G., see Morin, J.-P. (1) 69–79
Venketasubramanian, N., see Chai, Y.L. (4) 1111–1118
Verny, M., see Godefroy, O. (3) 815–825
Vialaret, J., see Barthélemy, N.R. (4) 1033–1043
Villemagne, V.L., see Ramanan, S. (2) 367–376
Viña, J., see Bonet-Costa, V. (3) 701–711
Vincent, A.J., see Southam, K.A. (3) 657–669
Viola, V., see Serra, L. (2) 377–389
Vrenken, H., see Louwersheimer, E. (2) 581–590
Walker, D.G., see Dugger, B.N. (2) 345–356
Wallon, D., see Grangeon, L. (3) 905–913
Wang, C., see Wang, H.-F. (1) 227–236
Wang, H.-F., L. Tan, L. Cao, X.-C. Zhu, T. Jiang, M.-S. Tan, Y. Liu, C. Wang, R.M. Tsai, J.-P. Jia, J.-T. Yu and Alzheimer’s Disease Neuroimaging Initiative, Application of the IWG-2 Diagnostic Criteria for Alz-heimer’s Disease to the ADNI (1) 227–236
Wang, H.-L., Y.-Y. Wang, X.-G. Liu, S.-H. Kuo, N. Liu, Q.-Y. Song and M.-W. Wang, Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer’s Disease: A Meta-Analysis (1) 45–55
Wang, J., see Chai, Y.L. (4) 1111–1118
Wang, M.-W., see Wang, H.-L. (1) 45–55
Wang, Q., see Li, W.-X. (2) 417–425
Wang, Q., see Yang, C.-c. (1) 33–44
Wang, T.J., see Karakis, I. (2) 451–461
Wang, Y.-Y., see Wang, H.-L. (1) 45–55
Wattjes, M.P., see Louwersheimer, E. (2) 581–590
White, M.T., L.M. Shaw, S.X. Xie, for the Alzheimer’s Disease Neuroimaging Initiative and the National Alzheimer’s Coordinating Center, Evaluation of Cerebrospinal Fluid Assay Variability in Alz-heimer’s Disease (2) 463–470
Whiteside, C.M., see Dugger, B.N. (2) 345–356
Whittum-Hudson, J.A., see Itzhaki, R.F. (4) 979–984
Wibom, M., see Smith, R. (2) 339–343
Willcox, D.C., see Nishihira, J. (3) 857–866
Witte, A.V., see Külzow, N. (3) 713–725
Wohlschläger, A.M., see Pasquini, L. (1) 313–326
Womack, K.B., see LoBue, C. (3) 727–736
Wong, B.-S., see Chai, Y.L. (4) 1111–1118
Wong, S., M. Bertoux, G. Savage, J.R. Hodges, O. Piguet and M. Hornberger, Comparison of Prefrontal Atrophy and Episodic Memory Performance in Dysexecutive Alzheimer’s Disease and Behavioral-Variant Fronto-temporal Dementia (3) 889–903
Woods, R.T., see Clare, L. (1) 139–150
Woon, F.L., see LoBue, C. (3) 727–736
Wu, X., see Xu, L. (4) 1045–1056
Wu, Y., see Chang, L. (1) 197–212
Wucherer, D., see Eichler, T. (3) 847–855
Xiang, Q., see Lou, G. (4) 985–990
Xiao, F., see Lou, G. (4) 985–990
Xiao, M., see Xu, Z.-Q. (1) 179–195
Xie, S.X., see White, M.T. (2) 463–470
Xu, F., see Chu, S. (2) 525–532
Xu, H., V.M. Perreau, K.A. Dent, A.I. Bush, D.I. Finkelstein and P.A. Adlard, Iron Regulates Apolipoprotein E Ex-pression and Secretion in Neurons and Astrocytes (2) 471–487
Xu, J., see Xu, Z.-Q. (1) 179–195
Xu, L., X. Wu, R. Li, K. Chen, Z. Long, J. Zhang, X. Guo and L. Yao and for the Alzheimer’s Disease Neuroimaging Initiative, Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers (4) 1045–1056
Xu, Z.-Q., H. Huang, Y.-L. Chen, Y.-Y. Gao, J. Xu, C. Marshall, Z.-Y. Cai and M. Xiao, Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis (1) 179–195
Yamamoto, Y., see Manousopoulou, A. (2) 333–338
Yan, Z., see Chang, L. (1) 197–212
Yang, C.-c., X.-x. Kuai, W.-b. Gao, J.-c. Yu, Q. Wang, L. Li and L. Zhang, Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration (1) 33–44
Yao, L., see Xu, L. (4) 1045–1056
Yao, Q., G.-X. Jiang, Z.-M. Zhou, J.-M. Chen and Q. Cheng, Metabolic Syndrome and Mild Cognitive Impairment: A Case-Control Study among Elderly in a Shanghai Suburb (4) 1175–1182
Yin, N.-N., see Hong, X.-P. (2) 605–617
Yoon, H., see Song, J.M., (2) 591–604
Yu, J.-c., see Yang, C.-c. (1) 33–44
Yu, J.-T., see Wang, H.-F. (1) 227–236
Yu, Q., see Fang, D. (2) 571–580
Yuan, F., see Hong, X.-P. (2) 605–617
Yuzawa, Y., see Sakai, K. (4) 997–1002
Zanusso, G., see Costassa, E.V. (3) 875–887
Zawia, N.H., see Masoud, A.M. (4) 1257–1264
Zhang, J., see Stern, R.A. (4) 1099–1109
Zhang, J., see Xu, L. (4) 1045–1056
Zhang, L., see Yang, C.-c. (1) 33–44
Zhang, Q., see Lou, G. (4) 985–990
Zhang, Y., see Chang, L. (1) 197–212
Zhang, Y.-H., see Hong, X.-P. (2) 605–617
Zhang, Z., see Fang, D. (2) 571–580
Zhou, W., see Chang, L. (1) 197–212
Zhou, Z.-M., see Yao, Q. (4) 1175–1182
Zhu, X.-C., see Wang, H.-F. (1) 227–236
Zimmer, C., see Pasquini, L. (1) 313–326
Zweig, J.A., see Gray, N.E. (2) 391–403
